Plain-English translation of NCT06787105 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of fruquintinib, a medication being used to treat advanced colorectal cancer in patients who have already tried other standard treatments. Researchers are collecting medical information and blood samples from patients receiving this medication in regular clinics across Germany. The goal is to understand how well the medication works outside of a controlled research setting and to identify which patients benefit most from this treatment.
Patients with advanced colorectal cancer often run out of treatment options after trying several standard chemotherapy drugs and other therapies. This study aims to gather real-world evidence about whether this medication is effective for these patients and to discover biological markers that might predict which patients will respond best to the treatment.
You likely qualify if…
You likely don't qualify if…
You will take fruquintinib as prescribed by your regular oncologist — this study does not involve a clinical trial with different treatment groups. Researchers will collect your medical records and information about how you are responding to the medication from routine clinic visits. You may also be asked to donate a blood sample and allow researchers to access archival tumor tissue to study biological markers that might predict treatment response. The study tracks your progress over time through regular clinical care, with some patients also completing surveys about their quality of life.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany